Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2009

View Archived Issues

Budesonide fails to prevent ipilimumab-induced diarrhea in advanced melanoma patients

Dainippon Sumitomo Pharma reports results from Q1 ending June 30, 2009

Novel MAP kinase p38 inhibitor effective in rat models of arthritis

Novel GlaxoSmithKline agents activate SIRT1

Bayer describes novel phosphatidylinositol 3-kinase inhibitors

French scientists disclose bisphosphonate-based vectors for targeting bone tissue

Orexo and Novartis sign exclusive worldwide licensing agreement for OX-17-related product

Arno initiates dosing in phase I clinical study of PDK1 inhibitor AR-12 in cancer

Biotie Therapies reaches milestone in Wyeth collaboration for PDE10 inhibitors for schizophrenia

Clinical trials of GAI-122 for prevention of delirium expected to begin by mid-2010

IDRI initiates phase I clinical trial of leishmaniasis vaccine candidate

Hisamitsu acquires Noven

Taisho developing mGlu5 receptor antagonists for anxiety

Novel ZAP-70 inhibitors reported to be in early development at Cellzome

Dainippon Sumitomo Pharma patents DPP IV inhibitors for diabetes

REG1 system induces controlled anticoagulation in phase IIa study in PCI patients

Research collaboration identifies possible new treatments for human African trypanosomiasis

Compounds inhibiting PI3 kinase designed by Wyeth for treating cancer

Facet Biotech and Trubion sign collaboration agreement for TRU-016 in CLL

Innate Pharma granted approval to initiate phase IIa trial of IPH-2101 for multiple myeloma

Health Canada approves Medicago's CTA for phase I human clinical trial of H5N1 vaccine

Takeda initiates EXAMINE cardiovascular outcomes trial of alogliptin for diabetes

Stallergenes names second sublingual desensitization tablet

Valcyte approved for prevention of CMV in pediatric transplant patients

RE-LY study reveals advantage of dabigatran over warfarin in atrial fibrillation patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...